Immunomodulation With Eltrombopag in ITP (iROM2)
Immunomodulation in Young and Midlife Adults With Newly Diagnosed Primary Immune Thrombocytopenia (ITP): A Randomized Open Label Trial With High-dose Dexamethasone Versus Eltrombopag and High-dose Dexamethasone
Sponsor: Novartis Pharmaceuticals
This PHASE2 trial investigates Primary Immune Thrombocytopenia (ITP) and is currently completed. Novartis Pharmaceuticals leads this study, which shows 11 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Feb 2024 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Apr 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE2
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
- Stiftung zur Förderung medizinischer und biologischer Forschung
- University Children's Hospital Basel
- University of Erlangen-Nürnberg, Department of Biology
For direct contact, visit the study record on ClinicalTrials.gov .